In both the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model and the MitoPark transgenic mouse model of PD, overexpression of PK2 is already observed in the first phase of neuronal degeneration before the onset of motor symptoms. Here, PROK2 is linked to Parkinson disease.